Altria Says It Has Engineered Around The Patent Problem That Pulled NJOY ACE Off Shelves
CEO Sal Mancuso says Altria plans to return to e-vapor, in a "disciplined" way, and estimates 20 million adult vapers, down 1 million.
Altria plans to get back into e-vapor: CEO Sal Mancuso said on the company's third-quarter earnings call Thursday that it has "worked around the patent issues" that forced it to pull Enjoy Ace from the market, though no return date has been announced.
A return, but no date
Altria, which makes and sells cigarettes, smokeless tobacco, oral nicotine pouches and NJOY e-vapor products to adult U.S. consumers, raised its 2026 earnings outlook the same day.
A Goldman Sachs analyst asked whether Altria would bring the product back soon and run it differently, citing the "substantial operating losses" the brand once posted. Mancuso said the approach would be "very disciplined," with the aim of competing "in a profitable way over time."
"We do plan on being back in the evapor market," he said, adding that the company has not announced when.
An illicit market still dominates
Mancuso said the e-vapor market, despite some improvement, is "still predominantly driven by the illicit category." Altria continues to engage stakeholders to drive and sustain enforcement against illegal products, and he said it is important for the FDA to authorize products more quickly.
Altria estimates about 20 million adult vapers at the end of September, down 1 million from a year earlier, primarily because fewer e-vapor consumers are using illicit products.
A Jefferies analyst asked where legal flavored vapes, which a competitor launched in August and September, might take share. Mancuso said flavors attract smokers to a less harmful product, but called the category "upside down" because illicit vapors, which have not been through the regulatory process, threaten the long-term harm-reduction opportunity.
FDA reviews under legal pressure
Mancuso said Helix, Altria's smoke-free unit, and Enjoy sued the FDA during the quarter, asking a court to require a review process that meets the 180-day timeframe set by Congress and to let products with applications pending beyond that window stay on the market. After the filing, he said, the FDA announced plans to evaluate changes to its premarket authorization framework and to pursue new rulemaking, which Altria welcomes.
Altria shares traded at $75.90, up about 4%, in Thursday trading.
Mancuso said Altria believes sustained enforcement and a more efficient authorization process are both necessary to establish a level playing field for legal manufacturers.
Sources
- Altria: Q3 Earnings Snapshot — Associated Press
- Altria Non-GAAP EPS of $1.52 beats by $0.01, revenue of $5.44B beats by $130M (MO:NYSE) | Seeking Alpha — seekingalpha.com
- Altria raises full-year outlook after Q3 2026 earnings beat — qz.com
- Altria in charts: Net revenue rises 1% to $6.1B, driven by smokeable products growth (MO:NYSE) | Seeking Alpha — seekingalpha.com
- Altria eleva su pronóstico anual después de superar las ganancias del tercer trimestre de 2026 — es.qz.com